Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia

Wyeth is now a wholly owned subsidiary of Pfizer559 enrolled

Overview

The study is a cross sectional, epidemiology study of disease severity for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in four geographic regions in Australia (Illawarra, Sutherland, Hunter Urban and Hunter Rural).

Study Type

OBSERVATIONAL

Enrollment

559

Conditions

Ankylosing Spondylitis Psoriatic Arthritis Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria include: Adult patients with a diagnosis of rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who have visited a primary care centre within one of the specified catchment areas for their condition within the last 24 months.

Locations (4)

Unnamed facility

Georgetown, Australia

Unnamed facility

Miranda, Australia

Unnamed facility

Newcastle, Australia

Unnamed facility

Wollongong, Australia

Outcomes

Primary Outcomes

Proportion of rheumatoid arthritis/psoriatic arthritis/ankylosing spondylitis patients in defined disease severity categories

Time frame: Single visit

Secondary Outcomes

Proportion of patients exposed to biological disease modifying antirheumatic drugs

Time frame: Single visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.